SLC5A2 and Stroke: In addition to decreasing the incidence of stroke, several studies suggest thatSGLT2 inhibitors may confer potential benefits in the context of ischemic stroke.In both nondiabetic and diabetic murine models, administering the SGLT2 inhibitorempagliflozin or luseogliflozin was associated with improved neurologicaloutcomes and reduced infarct volumes.